Mizodin (Primidone)

Primidone is converted in the body to phenobarbital, which enhances the activity of the inhibitory neurotransmitter GABA. This increased GABAergic inhibition reduces neuronal excitability, helping to prevent the abnormal electrical activity that leads to seizures.

The appropriate dose of Mizodin is determined individually by a prescribing healthcare professional based on the patient’s age, weight, seizure type, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mizodin in pregnancy and lactation are limited. The potential risks and benefits should be evaluated by a qualified clinician. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative options or close monitoring with their doctor.

To order Mizodin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mizodin (primidone) is often compared with phenobarbital, another barbiturate anticonvulsant. Both share a similar mechanism, but primidone may have a slightly different side‑effect profile and is sometimes preferred for its once‑daily dosing. Compared with newer agents such as levetiracetam, primidone is less expensive but may cause more sedation.

Mizodin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Mizodin is taken orally, usually with a glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable blood levels. Patients should swallow the tablet whole and not crush or chew it unless instructed otherwise.

Serious risks include severe skin reactions (e.g., Stevens‑Johnson syndrome), blood disorders such as agranulocytosis, respiratory depression especially when combined with other CNS depressants, and significant liver dysfunction. Any signs of rash, fever, unusual bleeding, or breathing difficulties should prompt immediate medical attention.

Mizodin is contraindicated in patients with known hypersensitivity to primidone, phenobarbital, or any barbiturate components. It should also be avoided in individuals with severe hepatic impairment or those taking medications that could cause life‑threatening interactions without close monitoring.